Slide 1: Investor Presentation: Capital Raising and Phyzhon Health Distribution Agreement
For personal use only Investor Presentation Capital Raising and Phyzhon Health Distribution Agreement 30 October 2020
Slide 2: Introducing Hydrix
Introducing Hydrix For personal use only At Hydrix, our vision is to improve a billion lives. We will achieve this vision by applying technology to develop and distribute products that enhance global health, safety and well- being.
Slide 3: Hydrix - powering growth and innovation
Hydrix - powering growth and innovation Modest margin, good cashflow, Higher margin, scalable, large For personal use only covers group costs, provides leads market opportunity Hydrix Medical Hydrix Services Diagnostic, monitoring & Hydrix Group’s powerful interventional MedTech product innovation e
Slide 4: Executive Summary
Executive Summary • Diversified medtech product design services and device business – 18-year history, Melbourne based, global customers For personal use only • “One stop shop” for bringing concepts through to commercialisation for medical devices / technology Company Overview • Assisted the develop
Slide 5: Hydrix Group: FY20 Financials & Outlook
Hydrix Group: FY20 Financials & Outlook FY20 near cash operating breakeven2 from Services revenue only and with COVID impact For personal use only Revenue Growth1 ($m) Key Insights • FY20 total revenue $15.9m, at end of 1HF20, HYD was on track to achieve 15%+ YoY growth rate and deliver a full year
Slide 6: Hydrix Services
For personal use only Hydrix Services
Slide 7: Powerful product innovation capability
Powerful product innovation capability For personal use only Established 2002 60+ employees Full-service NPD 200+ successful projects Specialist capabilities include: • Planning & Project Mgt • Device Engineering • HFE & Usability • Prototype development • Testing & Verification • Quality systems •
Slide 8: Hydrix Services: Transforming Ideas into Products
Hydrix Services: “Transforming Ideas into Products” ‘One-stop-shop’ design & engineering to assist Clients create ‘disruptive’ leading medical technologies For personal use only Micro-X (ASX:MX1) Memphasys (ASX:MEM) Gyder Surgical (unlisted) Portable X-Ray Machine Bio-separation Device Hip Replaceme
Slide 9: Hydrix Medical
For personal use only Hydrix Medical
Slide 10: Our Vision for Cardiac Patient Monitoring
Our Vision for Cardiac Patient Monitoring Building a synergistic portfolio of cardiac devices For personal use only A compelling market Patient opportunity Monitoring Clinical Benefits Cardiac monitoring devices • Cardiovascular disease Critical data has been pushed via communicate to smart afflicts
Slide 11: Hydrix Medical – Portfolio overview
Hydrix Medical – Portfolio overview For personal use only AngelMed Guardian Phyzhon LUDO Implanted Heart Monitor Interventional cardiology device Hydrix cardiac controller platform • 3rd party distribution agreement – signed • Exclusive rights to distribute in Australia & New • Hydrix cardiac contro
Slide 12: Product 1: AngelMed Guardian Value Proposition
Product 1: AngelMed Guardian® Value Proposition For personal use only World-first technology to assist cardiologists manage patient health & well-being Improved patient Reduced costs care Reduces false positive Detects previously hospital visits. Improved untreatable silent MIs, preservation of left
Slide 13: Product 1: The AngelMed Guardian Overview
Product 1: The AngelMed Guardian® Overview For personal use only Product: World’s first FDA approved implantable heart attack alert system using patented AI & Machine Learning algorithms – Continuous 24X7 heart monitor - detects heart-beat changes indicative of a potential heart attack and arrythm
Slide 14: Product 1: AngelMed Guardian Revenue Potential
Product 1: AngelMed Guardian® Revenue Potential A 3% capture rate of patient market = $100m rev p.a. (15,000 units) For personal use only Potential Market Size and Time to Commercialisation Potential Market Revenue @ 1%-5% Capture ACS4 Annual Sales Volume (units) Annual Sales Value (A$)5 Sell Pre- R
Slide 15: Product 2: Phyzhon FFR guidewire
Product 2: Phyzhon FFR guidewire Product: novel and market first, fibre optic pressure sensor guidewire used for interventional cardiology procedures For personal use only – Single use device used by cardiologists to take blood pressure measurements during surgical procedures which diagnose and ma
Slide 16: Product 2: Phyzhon's Revenue Potential
Product 2: Phyzhon’s Revenue Potential At 33% potential market share uplift due to disruptive benefits - $25m rev p.a. For personal use only Potential Market Size and Time to Commercialisation Potential Market Capture Rate & Revenue Potential Pressure Annual Sales Value (A$)6 Sell Pre- Regulatory Po
Slide 17: Hydrix Ventures
For personal use only Hydrix Ventures
Slide 18: Hydrix Ventures: invest or sweat equity in high potential medtech clients
Hydrix Ventures: invest or sweat equity in high potential medtech clients For personal use only Leverage product design through market commercialisation capabilities and experience of Hydrix Services to capture more of the value that it creates for its customers AngelMed Guardian Gyder Surgical Memp
Slide 19: Potential News Flow
For personal use only Potential News Flow
Slide 20: Potential news flow: next months
Potential news flow: next 12 months For personal use only • Further sales (implants) of AngelMed Guardian in Singapore • First implants of AngelMed Guardian in Australia under Authorised Prescriber Scheme (“APS”) – potential Dec Qtr CY20 • AngelMed USA submission of battery testing results to FDA -
Slide 21: Value Proposition: High potential for exponential product revenue growth
Value Proposition: High potential for exponential product revenue growth For personal use only • Long established powerful product innovation company, >200 client programs over 18 years • Multiple platforms for growth powered by world leading one-stop-shop new product design expertise • Significant
Slide 22: Capital Raising – Offer Details & Timetable
Capital Raising – Offer Details & Timetable For personal use only • Two Tranche Placement to raise approximately A$10.0m (“Placement”) Offer size & structure • ~$8m under existing placement capacity and ~$2m subject to shareholder approval • Bell Potter Securities is acting as Lead Manager to the Pl
Slide 23: Hydrix – a corporate snapshot
Hydrix – a corporate snapshot For personal use only Major Shareholders (as of 27 October 2020) Shares (m) % Capital Structure (as of 23 October 2020) John W King Nominees & Associates 18.6 14.8% Ticker HYD Patagorang Pty Ltd (Roger Allen Family a/c) 6.7 5.3% Share Price $0.33 Invia Custodian Pty Ltd
Slide 24: Board & Senior Management Team
Board & Senior Management Team Hydrix’s board and leadership teams have the experience and drive to ensure the success of the Company For personal use only Hydrix Board Gavin Coote Paul Wright Joanne Bryant Julie King Alyn Tai Executive Chairman Non-Executive Director Non-Executive Director Non-Exec
Slide 25: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Hydrix Limited (the “Company” or “Hydrix”). This presentation is being provided to investors for the sole purpose of providing preliminary background financial and other information to enable recipients to review the business ac
Slide 26: For personal use only
For personal use only hydrix.com 30-32 Compark Circuit Mulgrave VIC 3170 Australia ASX:HYD